Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032

Description

Acute Lymphoblastic Leukemia (ALL) is an aggressive form of Non-Hodgkin’s Lymphoma (NHL), most common among children under 5 years of age. Overall, about 4 of every 10 cases of ALL are in adults. The risk is slightly higher in males than in females, and higher in Caucasians. The risk of ALL increases after 50 years of age and is more likely to be fatal in adults than in children. Adult ALL has historically had a dismal prognosis, with limited treatment options and cure rates less than 40% due to higher-risk disease features and significant chemotherapy-associated toxicity.

Adult Acute Lymphoblastic Leukemia – Incidence (Epidemiology)

The total incident population of adult acute lymphoblastic leukemia (ALL) in the G7 markets is estimated to be XX in 2032 with a CAGR of 0.5%. The relapsed / refractory ALL population in G7 is expected to reach XXX by 2032 at a CAGR of 0.5%

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph-like ALL in adults. Cytokine receptor-like factor 2 ( CRLF2 ) rearrangement is found in approximately 50% of pediatric Ph-like B-cell acute lymphoblastic leukemia (B-ALL), and around 50% of CRLF2 + cases harbor JAK mutations. In Ph-like ALL patients without CRLF2 overexpression, fusions involving JAK2, ABL1, ABL2, and many other tyrosine kinases are common, and many are amenable to ABL-type inhibitors (tyrosine kinase inhibitors [TKIs]) (fusions involving ABL1, ABL2, CSF1R, or PDGFRB) or JAK inhibitors (rearrangements of JAK2 and EPOR). Thus, genomic characterization of Ph-like ALL has significant therapeutic implications with the emerging use of kinase inhibitors in this patient population. Therefore, it is imperative to establish the incidence and clinical/genomic features of Ph-like ALL in adults.

Current treatment regimens result in 5-year event-free survival rates that exceed 85% in children (aged 1–21); however, disease relapse is associated with a poor outcome and ALL remains the leading cause of cancer-related death in children and young adults (aged 21–39). In general, about 80% to 90% of adults will have complete remissions at some point during these treatments which means leukemia cells can no longer be seen in their bone marrow. Unfortunately, about half of these patients’ relapse, so the overall cure rate is in the range of 40% whereas 10% to 20% of patients of the patients will refractory to leukemia. The relapse/refractory Adult Acute Lymphoblastic Leukemia (aALL) is found close to 50%.

Traditionally, the four components of aALL treatment are induction, consolidation, maintenance, and central nervous system (CNS) prophylaxis. Most patients with aALL diagnosed, will receive hyper-CVAD regimen or standard chemotherapies for Ph negative ALL whereas tyrosine kinase inhibitors (TKIs) will be used in addition to the standard chemotherapies. Similar trends were found in all the country specific studies.

Adult Acute Lymphoblastic Leukemia – Current Market Size & Forecast Trends

The adult ALL therapy market size is expected to experience high growth throughout our study period, increasing from $XX billion in 2017 to $2.5 billion in 2030, representing 6.1 % annual growth. The opportunities to grow the market are evident, beginning from the epidemiology of the condition.

The primary drivers of market growth will be the continuous usage of the current treatments i.e., multi agent chemotherapies including Hyper-Cvad regimens and Tyrosine kinase inhibitors in the frontline adult ALL treatments. The relapsed/ refractory treatment market is driven by immunotherapies such as Blincyto/Blinatumomab (Amgen), Besponsa/ Inotuzumab ozogamicin (Bristol Meyers Squibb). We expect that with the uptake of the emerging treatments i.e., JZP-458 (Jazz Pharmaceuticals/Pfenex), Brexucabtagene autoleucel (Kite Pharma), Daratumumab (Janssen Biotech), AUTO 1 (Autolus) and PBCAR 0191 (Precision BioSciences) the market will increase double fold in the G7 countries. Despite new drug approvals, we also foresee slow growth in adult aALL current TKI therapy market growth due to small number of ALL patients.

Report Highlights

• Adult Acute Lymphoblastic Leukemia (aALL)– Current Market Trends
• Adult Acute Lymphoblastic Leukemia (aALL)– Current & Forecasted Cases across the G7 Countries
• Adult Acute Lymphoblastic Leukemia (aALL)– Market Opportunities And Sales Potential for Agents
• Adult Acute Lymphoblastic Leukemia (aALL)– Patient-based Market Forecast to 2032
• Adult Acute Lymphoblastic Leukemia (aALL)– Untapped Business Opportunities
• Adult Acute Lymphoblastic Leukemia (aALL)– Product Positioning Vis-a-vis Competitors’ Products
• Adult Acute Lymphoblastic Leukemia (aALL)– KOLs Insight